Myelodysplastic syndrome occurring after enfortumab vedotin treatment for metastatic urothelial carcinoma
Introduction Enfortumab vedotin is an antibody‐drug conjugate targeting Nectin‐4 for the treatment of advanced urothelial carcinoma in patients previously treated with platinum‐containing chemotherapy and immune checkpoint inhibitors. Common adverse events include rashes, peripheral neuropathy, and...
Gardado en:
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Wiley
2024-07-01
|
| Series: | IJU Case Reports |
| Assuntos: | |
| Acceso en liña: | https://doi.org/10.1002/iju5.12734 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|